CASI CASI Pharmaceuticals Dashboard

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Company profile

Ticker

CASI

Exchange

NASDAQ

Website

www.casipharmaceuticals.com/

CEO

Wei-Wu He

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...

Former names

ENTREMED INC

SEC CIK

0000895051

Corporate docs

Articles of Incorporation & Bylaws

IRS number

581959440

CASI stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More

3 Apr 21

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Yet again, some insiders were taking advantage of recent public share offerings. Biotechs and a real estate investment trust saw insider purchases, and an insider at a mortgage company returned once again.

12 Health Care Stocks Moving In Wednesday's After-Market Session

31 Mar 21

Gainers AzurRx BioPharma (NASDAQ:AZRX) stock rose 17.16% to $1.57 during Wednesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 32.32% of its average volume over the last 100 days. The company's market cap stands at $111.4 million.

34 Stocks Moving in Wednesday's Pre-Market Session

31 Mar 21

Gainers Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 52% to $3.54 in pre-market trading after the company announced better-than-expected Q4 sales.

64 Biggest Movers From Yesterday

25 Mar 21

36 Stocks Moving In Wednesday's Mid-Day Session

24 Mar 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in CASI Pharmaceuticals, Windtree Therapeutics, ChargePoint Holdings, FreightCar America, or AzurRx BioPharma?

31 Mar 21

NEW YORK, March 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASI, WINT, CHPT, RAIL, and AZRX.

CASI Pharmaceuticals Announces Full Year 2020 Financial Results

30 Mar 21

ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock

24 Mar 21

ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

23 Mar 21

CASI Pharmaceuticals To Host Business Update Call March 12, 2021

11 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

29 Mar 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart CASI financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	57.06M	57.06M	57.06M	57.06M	57.06M	57.06M
Cash burn (monthly)	5.84M	(positive/no burn)	5.07M	4.29M	2.68M	2.16M
Cash used (since last report)	20.83M	n/a	18.07M	15.31M	9.54M	7.69M
Cash remaining	36.23M	n/a	38.99M	41.76M	47.52M	49.37M
Runway (months of cash)	6.2	n/a	7.7	9.7	17.7	22.9

Beta Read what these cash burn values mean

Recent insider trades

CASI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
26 Mar 21	He Wei-Wu	Common Stock	Buy	Aquire P	Yes	No	2.05	3,000,000	6.15M	3,000,000
22 Dec 20	He Wei-Wu	Common Stock	Gift	Dispose G	No	No	0	380,000	0	4,683,994
17 Dec 20	Weihao Xu	Common Stock	Buy	Aquire P	Yes	No	2.63	2,279	5.99K	10,000
17 Dec 20	Weihao Xu	Common Stock	Buy	Aquire P	Yes	No	2.64	1,721	4.54K	7,721
16 Dec 20	Weihao Xu	Common Stock	Buy	Aquire P	Yes	No	2.44	2,000	4.88K	6,000
16 Dec 20	Weihao Xu	Employee Stock Option Common Stock	Grant	Aquire A	No	No	2.61	800,000	2.09M	800,000
23 Nov 20	He Wei-Wu	Common Stock	Buy	Aquire P	No	No	2.18	100,000	218K	5,063,994
20 Nov 20	He Wei-Wu	Common Stock	Buy	Aquire P	No	No	2.12	127,471	270.24K	4,963,994

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

CASI institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cyclacel Pharmaceuticals • Adaptimmune Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AB, absence, absent, accommodate, admitted, affiliated, Aid, allogeneic, allogenic, alter, alteration, AML, annum, attack, attestation, Avenue, banned, bear, began, BioCheck, BioInvent, Biosecurity, blocking, book, branch, California, Catalogue, cellular, Chancery, Chartwell, checkpoint, chosen, CIP, CITIC, Cleave, complaint, comprised, consecutive, consequential, constituted, constraint, conveyed, CRO, cybersecurity, de, deal, deducting, departure, derecognized, destruction, digit, disbursed, disbursement, distancing, DNA, doctrine, duty, easily, emphasized, ENMD, epitope, EU, evidenced, explicit, facto, factor, factory, fiduciary, forgiven, forum, franchise, GCP, guarantee, guaranteed, guard, haemopoietic, half, hamper, harmonized, heavily, hectare, heighten, highlighting, Hongkou, Huicheng, IDG, immunity, immunotherapy, impractical, inaction, inapplicable, ineligible, infection, inhibitory, Injury, Inline, install, installation, jointly, judgement, judgment, jurisdiction, Keytruda, leader, leadership, lender, licensor, lock, lucrative, MabThera, Maternity, MaxCyte, misappropriating, monthly, motivate, motivating, multinational, myelodysplastic, NaN, narrative, NCI, North, NPC, Oppenheimer, opportunity, overseen, Panacea, pandemic, parallel, paused, Paycheck, peak, peer, pembrolizumab, PPP, PPPFA, preserved, principle, proceeding, prosecuting, prosecution, Quan, rational, receptor, recourse, refuse, relief, remediation, remote, remotely, renegotiate, resolution, retrieval, retroactive, Rubicon, rulemaking, run, Rx, SBA, SEK, Shanghai, Shengbang, Sichuan, slowdown, spinoff, split, spread, stake, Standing, stipulated, stipulation, stored, strain, stringent, subscribe, subscription, substitute, susceptible, syndrome, systematic, talent, tiered, tranche, transfusion, transmitted, turn, twenty, underway, underwriting, underwritten, unfold, unlock, unpublished, unsuccessful, unwilling, vendor, vote, voting, waiting, warehouse, Weihao, workshop, Xu, Yuanda, Zhou

Removed: accredited, accurately, attribution, broad, clarification, collaborator, complexity, concentrated, conditionwill, confirmatory, CTA, enhance, follicular, formulating, impede, inflation, inInternal, kit, man, MINE, operated, permissible, progenitor, quantitative, radioactive, radioisotope, reflected, reformulate, refractory, regimen, RegistrationApplication, Rental, streamline, tentatively, theperformance, trialapproval

From filing 10-K 2020 FY